Moderna
MRNA
$49.91
+0.54%
Moderna, Inc. is a commercial-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, operating within the dynamic and high-risk biotech industry. The company is a recognized leader and platform innovator in the mRNA space, having rapidly validated its technology with its COVID-19 vaccine. The current investor narrative is dominated by the company's transition from a pandemic-driven revenue source to a diversified pipeline, with intense focus on clinical data readouts for its cancer vaccines and other infectious disease candidates, as evidenced by recent news highlighting both promising long-term data and investor impatience with commercialization timelines.…
MRNA
Moderna
$49.91
Related headlines
Investment Opinion: Should I buy MRNA Today?
Rating & Thesis: Hold. Moderna is a high-risk, high-reward biotech turnaround story where the promise of a diversified mRNA pipeline is currently outweighed by severe financial deterioration and uncertain commercialization timelines. The mixed analyst sentiment, with ratings ranging from Overweight to Underperform and an average price target implied by forward sales estimates, reflects this stalemate.
Supporting Evidence: The Hold rating is supported by four key data points. First, valuation has reset to a more reasonable PS of 5.90x from extreme highs, but remains speculative given negative earnings. Second, revenue is in steep decline (-29.08% YoY), with no clear near-term catalyst to reverse the trend. Third, profitability is deeply negative with a net margin of -121.83% and substantial cash burn. Fourth, while analyst revenue estimates average $6.82 billion, the wide range ($5.73B to $10.17B) indicates low consensus and high forecast risk.
Risks & Conditions: The two biggest risks are a faster-than-expected cash burn depleting reserves before pipeline products launch, and negative clinical data from key late-stage trials. This Hold would upgrade to a Buy if the company demonstrates a clear path to profitability, shows sustained quarterly revenue growth from new products, or if the stock price approaches the $22-30 support zone offering a greater margin of safety. It would downgrade to a Sell if quarterly cash burn accelerates beyond $500 million, key pipeline candidates fail, or revenue fails to show sequential growth for two consecutive quarters. The stock is currently fairly valued for its high-risk profile, trading at a discount to its pandemic-era multiples but a premium to profitable biotech peers.
Sign up to view all
MRNA 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The investment thesis hinges entirely on the successful translation of Moderna's deep pipeline (35 candidates) into commercial products before its cash reserves are depleted. While the valuation has corrected significantly and technical momentum is strong, the fundamental picture of declining revenue and massive losses is too severe to warrant a bullish stance. The base case of range-bound trading is most probable, as the market awaits concrete commercial data. The stance would upgrade to bullish on evidence of sustained revenue growth from non-COVID products and a reduction in quarterly cash burn below $300M. It would downgrade to bearish on a key clinical failure or an acceleration of cash burn.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Moderna's 12-month outlook, with a consensus price target around $64.88 and implied upside of +30.0% versus the current price.
Average Target
$64.88
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$40 - $65
Analyst target range
A modest group of 9 analysts cover the stock, with recent institutional ratings showing a mix of 'Overweight', 'Neutral/In Line/Sector Perform', and 'Underperform' actions, indicating a lack of strong consensus. The average revenue estimate for the forward period is $6.82 billion, with a wide range from $5.73 billion to $10.17 billion, highlighting significant uncertainty in the near-term commercial outlook. The average EPS estimate is $2.66, also with a broad range from $2.11 to $4.36. The wide dispersion in both revenue and EPS targets signals high uncertainty among analysts regarding the timing and magnitude of Moderna's pipeline commercialization, which can lead to elevated stock volatility. The pattern of recent ratings has been largely static, with firms maintaining existing positions (e.g., Piper Sandler maintaining Overweight, RBC maintaining Sector Perform) rather than making decisive upgrades or downgrades, suggesting a 'wait-and-see' approach pending more concrete clinical and commercial data.
Bulls vs Bears: MRNA Investment Factors
The bull and bear cases for Moderna are starkly defined, with the bear side currently holding stronger evidence based on deteriorating fundamentals. The most compelling bull arguments are technical momentum and a reset valuation, while the bear case is anchored in severe revenue contraction, deep losses, and unsustainable cash burn. The single most important tension in the investment debate is the timing and commercial success of Moderna's 35-candidate pipeline versus its rapidly depleting financial runway. If pipeline catalysts like the cancer vaccine are delayed or fail, the company's cash position could become critically strained, validating the bear thesis. Conversely, positive clinical data and accelerated commercialization could trigger a significant re-rating, supporting the bull case.
Bullish
- Strong Technical Uptrend: The stock has gained 89.18% over the past year and is trading at 78% of its 52-week range, indicating powerful momentum. A recent 10.45% gain over the past month, outperforming the S&P 500 by 5.85%, signals renewed buying interest.
- Valuation Reset to Historical Lows: The current Price-to-Sales (PS) ratio of 5.90x is significantly lower than the 17.05x recorded at the end of Q4 2025, representing a dramatic de-rating. This positions the stock at the lower end of its own historical range, potentially offering a value entry point if the pipeline delivers.
- Robust Pipeline with 35 Clinical Candidates: Moderna has a deep and diversified pipeline of 35 mRNA clinical candidates across infectious disease, oncology, and rare diseases. Recent news highlights promising long-term cancer vaccine data and positive early-stage data for a hantavirus vaccine, validating the platform's versatility beyond COVID-19.
- Strong Balance Sheet with Low Debt: The company maintains a healthy current ratio of 3.29 and a low debt-to-equity ratio of 0.22, providing financial flexibility. With $2.6 billion in cash (as of Q4 2025), it has a substantial war chest to fund its ambitious R&D programs.
Bearish
- Severe Revenue Contraction & Cash Burn: Q4 2025 revenue of $678 million represents a 29.08% year-over-year decline, highlighting the post-pandemic revenue cliff. The company reported a trailing twelve-month free cash flow of -$2.054 billion, indicating a heavy cash burn rate that threatens its $2.6 billion cash reserves.
- Deeply Unprofitable with Negative Margins: The company reported a net loss of $826 million in Q4 2025, with a net margin of -121.83%. Despite a gross margin of 33.33%, massive R&D spending of $775 million in the same quarter compresses operating margins to -126.4%.
- High Uncertainty in Commercial Timelines: Recent news notes investor impatience with the lengthy path to commercialization for promising assets like its cancer vaccine. The wide analyst revenue estimate range of $5.73B to $10.17B underscores significant uncertainty regarding the timing and magnitude of new product launches.
- Valuation Remains Speculative: With negative earnings, the primary valuation metric is a PS ratio of 5.90x, which is still a premium for a company with declining sales. The forward P/E is negative (-12.27), and the Price-to-Cash Flow ratio is -6.12, indicating the market is pricing in future success that is far from guaranteed.
MRNA Technical Analysis
The stock is in a powerful long-term uptrend, evidenced by a staggering 89.18% gain over the past year. With a current price of $51.59, it is trading at approximately 78% of its 52-week range ($22.28 to $59.55), indicating strong momentum but not yet at extreme overbought levels relative to its recent peak. Recent momentum shows a notable divergence; the stock has gained 10.45% over the past month but is down 1.77% over the past three months, suggesting a recent recovery from a pullback within the larger uptrend. This 1-month outperformance against the S&P 500's 4.6% gain, as shown by a relative strength of 5.85, signals renewed buying interest. Key technical levels are clearly defined, with immediate resistance near the 52-week high of $59.55 and strong support at the 52-week low of $22.28. A breakout above resistance would confirm the resumption of the primary bull trend, while a breakdown below support would signal a major trend reversal. The stock's beta of 1.06 indicates volatility roughly in line with the broader market, which is notable for a biotech name and suggests its price action is currently more driven by company-specific catalysts than sector-wide risk sentiment.
Beta
1.03
1.03x market volatility
Max Drawdown
-35.5%
Largest decline past year
52-Week Range
$22-$60
Price range past year
Annual Return
+82.5%
Cumulative gain past year
| Period | MRNA Return | S&P 500 |
|---|---|---|
| 1m | -1.0% | -0.1% |
| 3m | -5.0% | +12.0% |
| 6m | +69.4% | +8.8% |
| 1y | +82.5% | +22.9% |
| ytd | +61.7% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MRNA Fundamental Analysis
Revenue trajectory remains volatile and is currently in a declining phase, with Q4 2025 revenue of $678 million representing a 29.08% year-over-year contraction. This follows a highly uneven quarterly pattern, from $1.02 billion in Q3 to $142 million in Q2, indicating the company is navigating a steep post-pandemic revenue cliff as it transitions to newer products. The company is deeply unprofitable, reporting a net loss of $826 million and a net margin of -121.83% for Q4 2025, though the gross margin of 33.33% for that quarter shows the underlying product business can be profitable before massive operating expenses. These operating expenses, particularly R&D which was $775 million in Q4, are compressing margins as the company invests heavily in its expansive pipeline of 35 clinical candidates. Balance sheet and cash flow health is a critical concern; while the company maintains a strong current ratio of 3.29 and a low debt-to-equity ratio of 0.22, it reported negative free cash flow of $2.054 billion on a trailing twelve-month basis. This substantial cash burn underscores the company's dependence on its existing cash reserves of $2.6 billion (as of Q4 2025) to fund its ambitious clinical programs, highlighting significant financial risk if the path to commercialization for new products is delayed.
Quarterly Revenue
$678000000.0B
2025-12
Revenue YoY Growth
-0.29%
YoY Comparison
Gross Margin
+0.33%
Latest Quarter
Free Cash Flow
$-2.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MRNA Overvalued?
Given the company's negative net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. Moderna trades at a trailing PS ratio of 5.90x and an Enterprise Value-to-Sales (EV/Sales) of 6.99x. The forward-looking analyst revenue estimate of $6.82 billion suggests the market is pricing in a significant sales recovery. Comparing to industry averages is challenging with the provided data, but the PS ratio of 5.90x sits well below the company's own historical PS ratios from recent quarters, which have spiked above 75x during periods of minimal revenue. Historically, the stock's valuation has been extremely volatile, closely tied to revenue spikes from COVID vaccine sales. The current PS ratio near 5.9x is significantly lower than the 17.05x recorded at the end of Q4 2025, indicating the market has dramatically de-rated the stock as pandemic revenues faded. This positioning at the lower end of its own historical range suggests the market is currently pricing in a more conservative, post-pandemic growth story, presenting a potential value opportunity if the pipeline delivers, but also reflecting the real risk of fundamental deterioration if it does not.
PE
-4.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -13x~495x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Moderna faces severe financial risks stemming from its steep post-pandemic revenue decline of 29.08% YoY in Q4 2025 and a net margin of -121.83%. The company is burning cash at an alarming rate, with trailing twelve-month free cash flow of -$2.054 billion against cash reserves of $2.6 billion, implying a runway of roughly 1.3 years at the current burn rate without new revenue. This creates a high dependency on the success and timely commercialization of its pipeline. Furthermore, quarterly revenue volatility is extreme, ranging from $142 million to $1.02 billion over the past year, indicating a lack of a stable revenue base and making the business model inherently unpredictable.
Market & Competitive Risks: The stock's valuation, while lower than its historical peak, remains speculative with a PS ratio of 5.90x for a company with declining sales. This leaves it vulnerable to multiple compression if growth expectations are not met. The biotech sector is highly competitive and subject to clinical trial failures, regulatory hurdles, and rapid technological disruption, as evidenced by news of BioNTech's leadership crisis. Moderna's beta of 1.06 suggests its price moves with the market, but company-specific clinical data readouts are the primary driver of volatility, creating event risk around pipeline updates.
Worst-Case Scenario: The worst-case scenario involves a series of clinical setbacks in key pipeline programs (e.g., cancer vaccines), leading to significant delays or failures. This would force the company to continue funding R&D with its dwindling cash, accelerating the burn rate without a near-term revenue replacement for COVID vaccines. Combined with a broader market downturn compressing biotech valuations, the stock could re-test its 52-week low of $22.28. From the current price of $51.59, this represents a potential downside of approximately -57%. A more realistic bear-case target, aligned with analyst skepticism and sustained losses, could see the stock fall 35-45%.
FAQ
The key risks, in order of severity, are: 1) Financial Risk: The company is burning cash at an unsustainable rate, with TTM free cash flow of -$2.054B against $2.6B in reserves, threatening its ability to fund operations. 2) Clinical & Commercialization Risk: The company's future depends on the success of its 35 clinical candidates; any delays or failures in late-stage trials would severely damage the investment thesis. 3) Revenue Concentration & Decline: The company is navigating a steep post-pandemic revenue cliff, with Q4 2025 sales down 29.08% YoY, and lacks a stable replacement product. 4) Valuation & Sentiment Risk: The stock's price is highly sensitive to clinical news and analyst sentiment, leading to volatility, as evidenced by its 52-week range from $22.28 to $59.55.
The 12-month forecast for MRNA is highly bifurcated, with a base case target range of $45-$60 (50% probability), a bull case of $65-$75 (25% probability), and a bear case of $22-$35 (25% probability). The base case, which is most likely, assumes continued volatility with no major clinical failures or breakthroughs, revenue stabilizing from COVID vaccines, and the stock trading on pipeline updates. The bull case depends on positive late-stage data and accelerated commercialization, while the bear case is triggered by a clinical setback and worsening cash burn. The wide dispersion in analyst revenue estimates ($5.73B to $10.17B) underscores the high uncertainty in this forecast.
MRNA is fairly valued relative to its current fundamentals but speculatively valued relative to its future potential. With negative earnings, the primary metric is the Price-to-Sales (PS) ratio of 5.90x, which is a significant discount to its own historical PS ratio of 17.05x from late 2025. This suggests the market has already priced in the post-pandemic revenue decline. However, for a company with contracting sales (-29.08% YoY) and negative margins, this multiple still implies the market is paying for future growth that is not yet visible. Compared to profitable biotech peers, MRNA trades at a premium due to its platform potential. The valuation implies the market expects successful pipeline commercialization; failure to deliver would make the stock overvalued.
MRNA is a high-risk, high-potential reward stock that is not a good buy for most conservative investors. For aggressive investors with a long-term horizon and high risk tolerance, it may represent a speculative opportunity. The stock offers significant upside if its pipeline succeeds, with analyst revenue estimates implying a potential 900%+ sales recovery. However, this is counterbalanced by severe downside risk, including a 57% potential drop to its 52-week low of $22.28, driven by a cash burn of over $2 billion annually and deep operational losses. It could be a good buy for a small, speculative portion of a portfolio only if purchased on significant weakness, providing a larger margin of safety.
MRNA is unsuitable for short-term trading due to its high volatility driven by binary clinical trial outcomes and earnings reports. The stock's beta of 1.06 indicates market-correlated moves, but company-specific news causes larger swings. Given the company's stage—transitioning from a single-product company to a diversified biotech—the investment thesis will take years to play out. It is only suitable for long-term investors with a minimum 3-5 year horizon who can withstand potential drawdowns exceeding 50%. The lack of a dividend and current losses mean the only return potential is capital appreciation, which is entirely dependent on long-term pipeline success.